Cabotegravir
Names | |
---|---|
IUPAC name
N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.306.452 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C19H17F2N3O5 | |
Molar mass | 405.358 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Cabotegravir (USAN[1] and INN[2]; also known as S/GSK1265744 or GSK744) is an investigational new drug under development for the treatment of HIV infection. It is an integrase inhibitor, with a carbamoyl pyridone structure similar to dolutegravir.[3] In investigational studies, the agent has been packaged into nanoparticles (GSK744LAP) conferring an exceptionally long biological half-life of 21–50 days following a single dose. In theory, this would make possible suppression of HIV with dosing as infrequently as once every three months.[4]
Cabotegravir is being examined in the clinical trials HPTN 083 and HPTN 084.[5][6]
References
- ^ "Adopted USANs" (PDF). American Medical Association. Retrieved 19 September 2014.
- ^ "WHO Drug Information, Vol. 28, No. 2, 2014" (PDF). WHO Publications. Retrieved 19 September 2014.
- ^ Borrell, Brendan (2014). "Long-acting shot prevents infection with HIV analogue". Nature. doi:10.1038/nature.2014.14819.
- ^ PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3–6, 2013.
- ^ "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.
- ^ "The HIV Prevention Trials Network | Prevention Now". www.hptn.org. Retrieved 2017-12-02.